Medical University of South Carolina

Institutional Biosafety Committee Meeting Minutes

Meeting Date	Thursday, August 14, 2025
Meeting Time	12:06 PM – 2:02 PM
Meeting Type	Teams Meeting
IBC Members Present	1. Caroline Westwater, Ph.D., (IBC Chair) 2. John Woodward, Ph.D. (IBC Vice Chair) 3. Christina Voelkel-Johnson, Ph.D., (BSO) 4. Lisa Steed, Ph.D., (IBC Member) 5. Eric Meissner, M.D., (IBC Member) 6. Carlene Brandon, MS. (Local Non-affiliated Member)
Quorum	Number of Members Present (Voting):6 Number of Members Not Present:5 Late Arrival of Voting Members:0 Early Departure of Voting Members:0
Other Individuals in Attendance	Michael Smith, Ph.D., (IBC Manager) Gloriane Schnabolk Ph.D., (IACUC & IBC Senior Administrator) Aimee McRae-Clark, Pharm.D., BCPP (Office of Research Integrity Director)
Call to Order	The IBC Chair called the meeting to order at 12:06 PM
Conflicts of Interests	The IBC Chair reminded all members present to identify any conflicts of interest before each registration is reviewed.
Review and Approval of Previous Meeting Minutes	July 10, 2025, will be approved in the September meeting.
Review of Prior Business	New IBC Community Member, Carlene Brandon. IBC Meeting Minutes are posted on the IBC Meeting Dates & Deadlines page.
New IBC Registration and Amendments for Review (repeat for each registration)	

Protocol #	IBC-25-248
PI Name	Cunningham, Melissa
Study Title	[redacted]: A Phase 1 Study Evaluating the Safety and Preliminary Efficacy of [redacted] Allogeneic Car T Cell Product in Autoimmune Disease ([redacted])
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins

Formatted: Font color: Auto

	☐ Gene modified mouse cells ☐ Gene modified human cells ☒ Other CAR-T cell products
rDNA Category	III-D1a, III-C
Genetically modified microbes or vectors	rAAV6
Transgene expression	CD19 CAR+, CD70 CAR+
Highest BSL	BSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☐ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☐ Conditional approval with administrative post-review ☒ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Meissner
Votes			
For:6	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-255
PI Name	Flume, Patrick
Study Title	[redacted]: A Phase 2, Open-label, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Efficacy of [redacted] in People with Cystic Fibrosis
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☒ Other non-replicating mRNA being administered to human subjects
rDNA Category	III-D1a, III-C

Genetically modified microbes or vectors	N/A		
Transgene expression	human [redacted]		
Highest BSL	BSL2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☐ BSL2 ☒ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☐ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☐ Yes ☒ Precautions for at home administration		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Meissner	Second:	Voelkel-Johnson
Votes			
For:6	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-292
PI Name	Clifford, Robert
Study Title	A Phase 3a, observer-blind, randomized, controlled study to demonstrate lot-to-lot consistency and evaluate the immunogenicity and safety of an investigational varicella vaccine compared with Varivax, administered as a first dose to healthy children 12 to 15 months of age
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☒ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D1a, III-C
Genetically modified microbes or vectors	N/A
Transgene expression	[redacted]
Highest BSL	BSL2

Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☐ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☐ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☐ Yes ☒ Precautions for at home administration		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Meissner	Second:	Voelkel-Johnson
Votes			
For:6	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-267
PI Name	Tsao, Betty
Study Title	The identification of lupus risk variants and their roles in disease pathogenesis
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D1a, III-D2a
Genetically modified microbes or vectors	Baculoviral vector with mammalian promoter
Transgene expression	ATG16L2, ATG5, CLEC16A, NCF2, NCF1, DRAM1, CDKN1B, HIP1, at1, SAT1, LC3, Firefly Luciferase
Highest BSL	BSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ sealed tubes Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☒ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒

	Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Woodward	Second:	Voelkel-Johnson
Votes			
For:6	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-228		
PI Name	Jiang, Wei		
Study Title	Investigating the mechanism of neuropathogenesis of Alzheimer's disease in response to oral pathobionts		
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☒ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other		
rDNA Category	III-D1a		
Genetically modified microbes or vectors	[redacted]		
Transgene expression	N/A		
Highest BSL	BSL2, ABSL2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Steed	Second:	Westwater
Votes			
For:6	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-295		
PI Name	Cunningham, Melissa		
Study Title	The Role of Estrogen Receptor Alpha Variant Size and Localization in Modulating TLR7-Induced Inflammation		
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☒ Gene modified mouse cells ☒ Gene modified human cells ☐ Other		
rDNA Category	III-D2a		
Genetically modified microbes or vectors			
Transgene expression	ESR1 (ERα–46, ERα–66), GFP		
Highest BSL	BSL2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☐ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☒ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Voelkel-Johnson
Votes			
For:6	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-287
PI Name	Pereira Cardoso Azevedo, Estefania
Study Title	Neurobiology of Stress and Behavior
Agent	☒ Plasmid DNA/mRNA

	☒ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☒ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D1a
Genetically modified microbes or vectors	AAV, PRV, G-deleted SAD B19 rabies, HSV
Transgene expression	Opsins, Reporters, DREADDs, TVA, Glycoprotein G, Recombinases, mGLP1R, Optical sensors
Highest BSL	BSL2, ABSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☐ Conditional approval with administrative post-review ☒ Conditional approval with subcommittee post-review		
First:	Woodward	Second:	Westwater
Votes			
For:6	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-283
PI Name	Maddi, Abhiram
Study Title	Candida albicans glycosidases, Dfg5 and Dcw1, in virulence and pathogenesis
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☒ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells

	☐ Other		
rDNA Category	III-D2a		
Genetically modified microbes or vectors	Candida		
Transgene expression	HOG1, SLN1, DFG5 and DCW1		
Highest BSL	BSL2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☒ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Woodward
Votes			
For:6	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-279
PI Name	Long, David
Study Title	Regulation of chromatin dynamics and the interplay between transcription and DNA repair
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☒ Gene modified human cells ☐ Other
rDNA Category	III-D1a
Genetically modified microbes or vectors	Lentiviral vector

Transgene expression	BRD4, ATM, ATR, DNA-PK, BRCA1, BARD1, FANC genes, BRCA2.		
Highest BSL	BSL2		
Training	☒ Complete ☐ Pending		
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☒ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☒ Straight approval ☐ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Voelkel-Johnson
Votes			
For:6	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-274
PI Name	Lemasters, John
Study Title	CORE PROTOCOL - MUSC Cell & Molecular Imaging Shared Resource
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☐ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☐ Other
rDNA Category	III-D1a, III-D2a, III-D3a, III-D4b
Genetically modified microbes or vectors	Core user defined
Transgene expression	Core user defined
Highest BSL	BSL1/ABSL1 or BSL2/ABSL2: Core user defined
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐

	Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☒ Standard sharps precautions ☐ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐		
Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Westwater	Second:	Voelkel-Johnson
Votes			
For:6	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-271
PI Name	Bouchard, Michael
Study Title	Hepatitis B Virus Molecular Biology and Pathogenesis
Agent	☒ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☒ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☒ Gene modified mouse cells ☒ Gene modified human cells ☐ Other
rDNA Category	III-D1a, III-D2a
Genetically modified microbes or vectors	Adenoviral vectors; Lentiviral/Retroviral vectors
Transgene expression	BFP, CFP, GFP, EGFP, mCherry, Cox8-EGFP-mCherry); Tumor suppressor (p14), AMPKa, MP1, c7orf59, RPTOR, OMP25, LAMP3, TOMM20, TMEM192), mp18, DDB1, PARKIN
Highest BSL	BSL2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☐ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☐ Yes ☒ Centrifugation: N/A ☐ Sealed rotors/safety caps ☒ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Voelkel-Johnson	Second:	Westwater
Votes			
For:8	Against:0	Abstained:0	Recused:0

Protocol #	IBC-25-164
PI Name	Otis, James
Study Title	Neuroadaptation Produced by Acute PTSD-like Stress Create Vulnerability for Cannabis
Agent	☐ Plasmid DNA/mRNA ☐ CRISPR/Cas9 technology ☐ Molecular grade Escherichia coli ☐ Laboratory grade strains Saccharomyces cerevisiae ☒ Replication-deficient viral vectors ☐ RG1 microbes ☐ RG2 microbes ☐ Biological toxins ☐ Gene modified mouse cells ☐ Gene modified human cells ☒ Other DREADDs
rDNA Category	III-D1a, III-D4b
Genetically modified microbes or vectors	Adeno-Associated Virus
Transgene expression	Cre recombinase, FLpO recombinase, hM3Dq, hM3Di, GFP, YFP and mCherry
Highest BSL	BSL2, ABSL-2
Training	☒ Complete ☐ Pending
Risk Assessment of Procedures	PPE is appropriate for ☐ BSL1 ☒ BSL2 ☐ ABSL1 ☒ ABSL2 Waste handling: ☒ Chemical inactivation ☒ Physical inactivation Aerosol handling: N/A ☒ Yes ☐ Centrifugation: N/A ☒ Sealed rotors/safety caps ☐ Sharps handling: N/A ☐ Standard sharps precautions ☒ Transport: N/A ☐ Double sealed, durable leak-proof container with biohazard label ☒ Any special considerations No ☒ Yes ☐

Motion	☐ Straight approval ☒ Conditional approval with administrative post-review ☐ Conditional approval with subcommittee post-review		
First:	Voelkel-Johnson	Second:	Westwater
Votes			

For:6	Against:0	Abstained:0	Recused:0

Meeting Adjournment	The IBC Chair called for the meeting to be adjourned at 2:02 PM